MX354955B - Benzimidazoles y benzopirazoles sustituidos como antagonistas de ccr(4). - Google Patents
Benzimidazoles y benzopirazoles sustituidos como antagonistas de ccr(4).Info
- Publication number
- MX354955B MX354955B MX2014006514A MX2014006514A MX354955B MX 354955 B MX354955 B MX 354955B MX 2014006514 A MX2014006514 A MX 2014006514A MX 2014006514 A MX2014006514 A MX 2014006514A MX 354955 B MX354955 B MX 354955B
- Authority
- MX
- Mexico
- Prior art keywords
- ccr
- benzopyrazoles
- antagonists
- substituted benzimidazoles
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
Se proporcionan compuestos de benzimidazol, benzopirazol y benzotriazol que se unen a CCR(4) y son útiles para el tratamiento de enfermedades tales como enfermedades alérgicas, enfermedades autoinmunes, rechazo de injerto y cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161565973P | 2011-12-01 | 2011-12-01 | |
PCT/US2012/067299 WO2013082429A1 (en) | 2011-12-01 | 2012-11-30 | Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014006514A MX2014006514A (es) | 2014-07-10 |
MX354955B true MX354955B (es) | 2018-03-27 |
Family
ID=47324474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014006514A MX354955B (es) | 2011-12-01 | 2012-11-30 | Benzimidazoles y benzopirazoles sustituidos como antagonistas de ccr(4). |
Country Status (14)
Country | Link |
---|---|
US (4) | US8685959B2 (es) |
EP (1) | EP2785710B1 (es) |
JP (1) | JP6141863B2 (es) |
KR (1) | KR102031846B1 (es) |
CN (1) | CN103974950B (es) |
AU (1) | AU2012345779B2 (es) |
BR (1) | BR112014013150A2 (es) |
CA (1) | CA2856831C (es) |
DK (1) | DK2785710T3 (es) |
ES (1) | ES2648340T3 (es) |
HK (1) | HK1202866A1 (es) |
MX (1) | MX354955B (es) |
PT (1) | PT2785710T (es) |
WO (1) | WO2013082429A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9361365B2 (en) | 2008-05-01 | 2016-06-07 | Primal Fusion Inc. | Methods and apparatus for searching of content using semantic synthesis |
CN103974950B (zh) | 2011-12-01 | 2016-12-21 | 凯莫森特里克斯股份有限公司 | 作为ccr(4)拮抗剂的取代的苯并咪唑类和苯并吡唑类 |
AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
WO2014175370A1 (ja) * | 2013-04-25 | 2014-10-30 | 塩野義製薬株式会社 | ピロリジン誘導体およびそれらを含有する医薬組成物 |
AU2014284616B2 (en) * | 2013-06-21 | 2019-02-28 | Zenith Epigenetics Ltd. | Novel bicyclic bromodomain inhibitors |
CA2915622C (en) | 2013-06-21 | 2020-08-18 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
CA2919948C (en) | 2013-07-31 | 2020-07-21 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
GB201321740D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
CA2966303A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
CA2966449A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
JP2017538721A (ja) | 2014-12-17 | 2017-12-28 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | ブロモドメインの阻害剤 |
CN104622874B (zh) * | 2015-02-15 | 2017-12-26 | 中国科学院生物物理研究所 | Ccr4拮抗剂在抑制癌生长及转移中的应用 |
MX2019001223A (es) * | 2016-07-29 | 2019-11-11 | Flx Bio Inc | Moduladores de receptores de quimioquina y usos de los mismos. |
US10246462B2 (en) | 2016-09-09 | 2019-04-02 | Flx Bio, Inc. | Chemokine receptor modulators and uses thereof |
EP3548034A4 (en) * | 2016-12-05 | 2020-07-08 | Microbiotix, Inc. | BROADBAND SPECTRUM INHIBITORS OF FILOVIRUS |
WO2018187509A1 (en) * | 2017-04-04 | 2018-10-11 | Flx Bio, Inc. | Heterocyclic compounds as chemokine receptor modulators |
US10800760B2 (en) | 2017-05-31 | 2020-10-13 | Nantbio, Inc. | Trk inhibition |
KR20200104291A (ko) | 2017-11-06 | 2020-09-03 | 랩트 테라퓨틱스, 인크. | 항암제 |
JP7355758B2 (ja) * | 2018-01-26 | 2023-10-03 | ラプト・セラピューティクス・インコーポレイテッド | ケモカイン受容体調節剤及びその使用 |
JP2022539830A (ja) | 2019-07-10 | 2022-09-13 | ケモセントリックス,インコーポレイティド | Pd-l1阻害剤としてのインダン |
WO2023143194A1 (zh) * | 2022-01-25 | 2023-08-03 | 瑞石生物医药有限公司 | 一种ccr4小分子拮抗剂及其用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
WO1998005327A1 (en) * | 1996-08-05 | 1998-02-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted aromatic compounds |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
WO2006045478A1 (en) * | 2004-10-27 | 2006-05-04 | F. Hoffmann-La Roche Ag | New indole or benzimidazole derivatives |
CA2598489A1 (en) * | 2005-02-16 | 2006-08-24 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
WO2007111227A1 (ja) * | 2006-03-24 | 2007-10-04 | Astellas Pharma Inc. | アシルアミノピペリジン化合物 |
JP2010208945A (ja) * | 2007-06-01 | 2010-09-24 | Mitsubishi Tanabe Pharma Corp | 複素環化合物 |
CN102459227B (zh) * | 2009-04-17 | 2014-08-20 | 詹森药业有限公司 | Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂 |
CN103974950B (zh) | 2011-12-01 | 2016-12-21 | 凯莫森特里克斯股份有限公司 | 作为ccr(4)拮抗剂的取代的苯并咪唑类和苯并吡唑类 |
-
2012
- 2012-11-30 CN CN201280058945.8A patent/CN103974950B/zh active Active
- 2012-11-30 MX MX2014006514A patent/MX354955B/es active IP Right Grant
- 2012-11-30 CA CA2856831A patent/CA2856831C/en active Active
- 2012-11-30 JP JP2014544923A patent/JP6141863B2/ja active Active
- 2012-11-30 ES ES12798574.5T patent/ES2648340T3/es active Active
- 2012-11-30 WO PCT/US2012/067299 patent/WO2013082429A1/en active Application Filing
- 2012-11-30 KR KR1020147018282A patent/KR102031846B1/ko active IP Right Grant
- 2012-11-30 PT PT127985745T patent/PT2785710T/pt unknown
- 2012-11-30 AU AU2012345779A patent/AU2012345779B2/en active Active
- 2012-11-30 US US13/691,589 patent/US8685959B2/en active Active
- 2012-11-30 DK DK12798574.5T patent/DK2785710T3/en active
- 2012-11-30 BR BR112014013150A patent/BR112014013150A2/pt not_active IP Right Cessation
- 2012-11-30 EP EP12798574.5A patent/EP2785710B1/en active Active
-
2013
- 2013-10-17 US US14/056,702 patent/US9150550B2/en active Active
-
2015
- 2015-04-07 HK HK15103396.7A patent/HK1202866A1/xx unknown
- 2015-08-25 US US14/834,836 patent/US9790204B2/en active Active
-
2017
- 2017-09-12 US US15/702,427 patent/US10647696B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
HK1202866A1 (en) | 2015-10-09 |
EP2785710A1 (en) | 2014-10-08 |
JP6141863B2 (ja) | 2017-06-07 |
KR20140097552A (ko) | 2014-08-06 |
BR112014013150A2 (pt) | 2017-06-13 |
US9790204B2 (en) | 2017-10-17 |
CN103974950B (zh) | 2016-12-21 |
US9150550B2 (en) | 2015-10-06 |
WO2013082429A1 (en) | 2013-06-06 |
AU2012345779A1 (en) | 2014-06-12 |
US8685959B2 (en) | 2014-04-01 |
US20140121195A1 (en) | 2014-05-01 |
US20180127395A1 (en) | 2018-05-10 |
MX2014006514A (es) | 2014-07-10 |
ES2648340T3 (es) | 2018-01-02 |
US20160185756A1 (en) | 2016-06-30 |
CA2856831C (en) | 2020-02-18 |
KR102031846B1 (ko) | 2019-10-14 |
EP2785710B1 (en) | 2017-09-20 |
CA2856831A1 (en) | 2013-06-06 |
PT2785710T (pt) | 2017-12-18 |
US10647696B2 (en) | 2020-05-12 |
US20130165423A1 (en) | 2013-06-27 |
AU2012345779B2 (en) | 2017-04-06 |
DK2785710T3 (en) | 2017-12-04 |
CN103974950A (zh) | 2014-08-06 |
JP2015500240A (ja) | 2015-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014006514A (es) | Benzimidazoles y benzopirazoles sustituidos como antagonistas de ccr(4). | |
MX356163B (es) | Anilinas sustituidas como antagonistas de ccr(4). | |
PH12014502010A1 (en) | Bispecific antibodies against human tweak and human il17 and uses thereof | |
PH12015500983A1 (en) | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections | |
MX2012010404A (es) | Inhibidores heterociclicos de los receptores de histamina para el tratamiento de enfermedades. | |
EA201690461A1 (ru) | Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она | |
IN2015MN00478A (es) | ||
MX2019000225A (es) | Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
EA201270619A1 (ru) | Применение бетанехола для лечения ксеростомии | |
MX2012001419A (es) | Compuestos biciclicos novedosos de urea. | |
MX353299B (es) | Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer. | |
WO2013169574A3 (en) | Aliphatic spirolactam cgrp receptor antagonists | |
MX2013012652A (es) | Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12. | |
MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
MX360774B (es) | Antagonistas de progesterona. | |
MX2012001413A (es) | Compuestos azaheterociclicos novedosos. | |
EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 | |
MX2015017853A (es) | Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina de metodos de uso. | |
MX342947B (es) | Tratamiento de diabetes tipo 2. | |
PH12015502829A1 (en) | Lectin-like oxidized ldl receptor1 antibodies and methods of use | |
MX2015011518A (es) | Agentes de enlace de met y usos de los mismos. | |
MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
EA201290744A1 (ru) | Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов | |
MX2013011629A (es) | Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |